| 前收市價 | 8.48 |
| 開市 | 8.50 |
| 買盤 | 8.60 x 800 |
| 賣出價 | 8.64 x 800 |
| 今日波幅 | 8.50 - 8.88 |
| 52 週波幅 | 8.12 - 15.09 |
| 成交量 | |
| 平均成交量 | 310,477 |
| 市值 | 414.521M |
| Beta 值 (5 年，每月) | 1.63 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.77 |
| 業績公佈日 | 2023年10月04日 - 2023年10月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 27.42 |
Insider Monkey11 Cheap Small-Cap Stocks to Buy Before the Next Breakout
In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Cap Stocks to Buy Before the Next […]
BenzingaGilead Exercises First License Option Under Agreement With Nurix Therapeutics
Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases. Under the terms of the Collaboration, Nurix will
